HLS Therapeutics Inc.
HLTRF
$2.72
$0.082.96%
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 14.67M | 12.86M | 15.20M | 13.51M | 14.17M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 14.67M | 12.86M | 15.20M | 13.51M | 14.17M |
| Cost of Revenue | 4.56M | 4.19M | 4.28M | 3.81M | 3.87M |
| Gross Profit | 10.12M | 8.67M | 10.92M | 9.70M | 10.30M |
| SG&A Expenses | 5.75M | 5.35M | 5.22M | 5.57M | 5.60M |
| Depreciation & Amortization | 5.53M | 5.54M | 5.46M | 5.51M | 5.48M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 15.83M | 15.08M | 14.96M | 14.89M | 14.95M |
| Operating Income | -1.16M | -2.22M | 237.00K | -1.37M | -778.00K |
| Income Before Tax | -1.01M | -2.30M | -1.98M | -3.94M | -2.50M |
| Income Tax Expenses | 13.00K | 2.00K | -647.00K | -17.00K | 242.00K |
| Earnings from Continuing Operations | -1.02M | -2.30M | -1.34M | -3.92M | -2.74M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.02M | -2.30M | -1.34M | -3.92M | -2.74M |
| EBIT | -1.16M | -2.22M | 237.00K | -1.37M | -778.00K |
| EBITDA | 4.37M | 3.32M | 5.18M | 4.14M | 4.71M |
| EPS Basic | -0.03 | -0.07 | -0.04 | -0.12 | -0.09 |
| Normalized Basic EPS | -0.02 | -0.05 | -0.04 | -0.08 | -0.05 |
| EPS Diluted | -0.03 | -0.07 | -0.04 | -0.12 | -0.09 |
| Normalized Diluted EPS | -0.02 | -0.05 | -0.04 | -0.08 | -0.05 |
| Average Basic Shares Outstanding | 31.27M | 31.27M | 33.38M | 31.40M | 31.64M |
| Average Diluted Shares Outstanding | 31.27M | 31.27M | 33.38M | 31.40M | 31.64M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |